In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire to buy Roberts in $980mm stock swap

Executive Summary

Shire Pharmaceuticals is buying Roberts Pharmaceuticals (in-licenses drugs) in a $980mm stock swap that values each Roberts common share at about $30.71, a (pr)26% premium to its 10-day pre-announcement trading average. Post merger, Shire shareholders will hold 56% of the new company, and Roberts' will control the rest. The deal is expected to close in the fourth quarter of 1999.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies